Serum Endocan Level and the Severity of Coronary Artery Disease: A Pilot Study. (September 2015)

• Record Type: Journal Article
• Authors: Kose, Murat; Emet, Samim; Akpinar, Timur Selcuk; Kocaaga, Mehmet; Cakmak, Ramazan; Akarsu, Murat; Yuruyen, Gulden; Arman, Yucel; Tukek, Tufan
• Is Part Of: Angiology. Volume 66:Number 8(2015)
• Page Start: 727
• Page End: 731
• Publication Date: 2015-09
• Subjects: endocan -- endothelial-specific molecule 1 -- acute coronary syndrome -- Gensini score -- coronary artery disease -- SYNTAX score; Blood-vessels -- Diseases -- Periodicals; Cardiovascular system -- Diseases -- Periodicals; 616.13005
• DOI: 10.1177/0003319714548870
• Languages: English
• ISSNs: 0003-3197

Abstract

Endothelial-specific molecule 1 (endocan) is expressed in endothelial cells. We investigated the relationship between acute coronary syndrome (ACS) and serum endocan levels. We included 30 individuals as a control group and 53 patients diagnosed with ACS. The severity of coronary artery disease was assessed by a modified Gensini stenosis and SYNTAX scoring system. There was a significant difference in serum endocan levels between the control group and the ACS group (0.75 ± 0.13 vs 0.86 ± 0.25 ng/mL, P = .014). There was also a significant difference in serum endocan levels between diabetic patients with ACS and nondiabetic patients with ACS (1.02 ± 0.33 vs 0.81 ± 0.21 ng/mL, P = .016). There was no significant correlation between serum endocan level, Gensini, and SYNTAX score ( r = .11, P = .53 and r = .16, P = .37). Endocan, a new biomarker of endothelial pathology, is significantly increased in patients with ACS.